LONDON – Research and health emerged as the biggest losers following a marathon four days of negotiations by EU leaders on the bloc’s €1.1 trillion (US$1.3 trillion) 2021 - 2027 budget and the formation of a €750 billion (US$872 billion) pandemic recovery fund. Rather than €94.4 billion over the next seven years as proposed, the R&D program Horizon Europe, will get €80.9 billion.

HONG KONG- Boehringer Ingelheim International GmbH and Roche Holding AG have announced new initiatives to seek R&D collaborations in China, increasing both their footprint in China and China’s global biopharma presence. Boehringer Ingelheim announced earlier this month the launch of an External Innovation Hub in Shanghai. Meanwhile, Roche China also launched a collaboration initiative this week to develop therapies for gastrointestinal cancer.

HONG KONG- Boehringer Ingelheim International GmbH and Roche Holding AG have announced new initiatives to seek R&D collaborations in China, increasing both their footprint in China and China’s global biopharma presence. Boehringer Ingelheim announced earlier this month the launch of an External Innovation Hub in Shanghai. Meanwhile, Roche China also launched a collaboration initiative this week to develop therapies for gastrointestinal cancer.

Royalty deals by an investor into a particular pharmaceutical company program are not unheard of. This structure allows the investor to secure a portion of that specific anticipated upside, while enabling the pharma to fully fund R&D for that program without having to sacrifice other priorities to do so.

BEIJING – Suzhou, China-based Innovent Biologics Inc. is known in China as one of the first drugmakers to launch a PD-1 monoclonal antibody. Now, the company is moving to expand its product portfolio and enhance efforts in developing bispecific antibodies and cell therapies in a potential multibillion-dollar deal with pharma giant Roche Holding AG.

SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed.

SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed.

LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world.

LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world. The COVID-19 Host Genetics Initiative (CHGI), set up by scientists at the Institute for Molecular Medicine Finland (FIMM), now includes 151 registered studies that are searching for genetic variation associated with severity and outcomes.

LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world.